November 10, 2012: BioAegis Therapeutics Exercises Option for Exclusive License to Recombinant Human Plasma Gelsolin from Brigham and Women's Hospital

November 10, 2012: BioAegis Therapeutics Exercises Option for Exclusive License to Recombinant Human Plasma Gelsolin from Brigham and Women’s Hospital

November 10, 2012

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 10, 2012) Pursuant to the terms of the agreement with the Brigham and Women’s Hospital previously announced on May 11, 2011, BioAegis Therapeutics elected to exercise its option into an exclusive license to recombinant human plasma gelsolin technology.

November 10, 2012: BioAegis Therapeutics Exercises Option for Exclusive License to Recombinant Human Plasma Gelsolin from Brigham and Women’s Hospital

Stay informed of our latest discoveries and news.

GENERAL NEWS/MEDIA

September 12, 2024: BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC

February 27, 2024: BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

October 16, 2023: BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

EVENTS

September 10-12, 2024: 6th Annual Inflammasome Therapeutics Summit

September 18-19, 2024: MedInvest Biotech & Pharma Investor Conference

COMPANY DETAILS

JOIN OUR TEAM

PRODUCT FAQS

FOLLOW US